Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-20 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
21/08/26	SEK 0.8190	-6.93%	4,879,923
19/08/26	SEK 0.8800	-2.22%	1,099,025
18/08/26	SEK 0.9000	-5.06%	1,203,549
17/08/26	SEK 0.9480	-2.77%	800,829
14/08/26	SEK 0.9750	-2.69%	1,335,012

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 00:00:00 21/08/2026 HKT			5-day change	1st Jan Change
0.8190 ^SEK	-6.93%		-18.26%	-1.21%

05:05pm	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
03:10pm	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW

Market Cap	178M 18.82M 16.11M 15.03M 13.79M 25.92M 1.8B 26.43M 69.51M 902M 70.65M 69.12M 2.99B	P/E 2026 *	-3.26x	P/E 2027 *	-2.32x
Enterprise Value	162M 17.13M 14.67M 13.68M 12.56M 23.59M 1.64B 24.06M 63.28M 821M 64.31M 62.91M 2.72B	EV / Sales 2026 *	5.18x	EV / Sales 2027 *	-
Free-Float	82.23%	Yield 2026 *	-	Yield 2027 *	-

05:05pm	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
03:10pm	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
01:53pm	Alzinova reports reduced operating loss	FW
12:03pm	Calendar Thursday, August 20	FW
06-24	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
06-24	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
06-24	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW
05-26	Calendar Tuesday May 26	FW
05-25	Calendar Tuesday May 26	FW
05-21	Alzinova secures 80 percent of TO4 warrants	FW

03:10pm	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
04-08	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
03-26	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
06/10/25	Alzinova gets fast track designation from US FDA	RE

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Course Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

07:25pm	Alzinova (Q2 Review): Capitalizing on diagnostics opportunities	AQ
01:46pm	Alzinova publishes interim report for the period January - June 2026	AQ
07-07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B	AQ
06-24	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ
06-24	Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test	AQ

1 day	-6.93%
1 week	-18.26%
Current month	-29.40%
1 month	+24.28%
3 months	+56.00%
6 months	+23.16%
Current year	-1.21%

1 week	0.75	1.04
1 month	0.61	1.23
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	-6.93%	-18.26%	-27.14%	-74.00%	18.87M
LONZA GROUP AG	+1.14%	+2.27%	+2.38%	+24.66%	50.5B
REVOLUTION MEDICINES, INC.	-2.50%	+3.29%	+477.00%	+598.50%	46.01B
BEONE MEDICINES AG	-1.05%	+4.56%	+20.22%	+89.62%	42.85B
IQVIA HOLDINGS INC.	+3.91%	+7.51%	+35.21%	+21.13%	41.03B
CELLTRION, INC.	0.00%	-3.91%	+17.87%	+47.98%	32.02B
MEDPACE HOLDINGS, INC.	+1.50%	+6.08%	+32.55%	+150.97%	16.98B
ASCENDIS PHARMA A/S	-1.29%	+4.46%	-	-	17.05B
EUROFINS SCIENTIFIC SE	+3.06%	+3.88%	+5.81%	+35.45%	14.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.62%	+4.95%	+84.97%	+46.92%	13.84B
Average	-0.04%	+1.35%	+72.10%	+104.58%	27.46B
Weighted average by Cap.	+0.50%	+2.37%	+103.91%	+150.43%

	2026 *	2027 *
Net sales	31.35M 3.31M 2.83M 2.64M 2.42M 4.56M 317M 4.65M 12.22M 159M 12.42M 12.15M 525M	-
Net income	-3.2M -338K -289K -270K -248K -465K -32.31M -474K -1.25M -16.19M -1.27M -1.24M -53.61M	-50.35M -5.31M -4.55M -4.24M -3.89M -7.32M -508M -7.46M -19.63M -255M -19.95M -19.51M -843M
Net Debt	-16M -1.69M -1.45M -1.35M -1.24M -2.33M -162M -2.37M -6.24M -80.96M -6.34M -6.2M -268M	-19M -2M -1.72M -1.6M -1.47M -2.76M -192M -2.82M -7.41M -96.14M -7.53M -7.36M -318M